Chemotherapy and EGFR inhibitor therapy
Two to four cycles of induction chemotherapy followed by concurrent chemoradiotherapy were given to all patients. EGFR-positive patients received Nimotuzumab, while EGFR-negative patients received Cetuximab (Table 2). All patients received oral mucositis prophylaxis followed by conventional mucositis treatment combined with quinolone antibiotics [4].